UGP2 and neoplasm: Our discovery that UGP2 acts as a tumor-suppressive factor in CRC indicates that its downregulation drives malignant progression and is associated with poor clinical outcomes, highlighting its potential as a dual-purpose diagnostic and prognostic candidate biomarker.